Last updated: 2026-09-14 22:47:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Lakewood-Amedex Biotherapeutics Inc. (LABT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2,17, with a market capitalization of $5,26M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,66 to $98,20. This page covers its latest market performance, valuation, price trends and company information.
$5,26M | |
$2,25 | |
$98,20 | |
$1,66 | |
$2,22 | |
54,99K | |
1,86M | |
-- | |
$98,20 | |
$1,66 | |
-- | |
-- |
Lakewood-Amedex Biotherapeutics Inc. (LABT) is trading at $2,14 in after-hours trading as of 2026-09-14 22:30:00, down 3,51% ($0,08) from the regular-session close of $2,22.
After-hours trading shows how investors are pricing LABT after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Lakewood-Amedex Biotherapeutics Inc. (LABT) moved from $2,07 to $2,17, representing a gain of 4,83% ($0,10).
The stock traded between $1,86 and $2,64 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 982,16 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0,5%
LABT is currently trading at $2,17, placing it 0,5% of the way from its 52-week low of $1,66 to its 52-week high of $98,20. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Lakewood-Amedex Biotherapeutics Inc. (LABT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.